Eligible patients who give informed consent will be offered a NaF -PET/MRI scan

Chronic Recurrent Multifocal Osteomyelitis

PET/MRI scan after injection of 18F-labelled sodium fluoride

18F-NaF-PET/MRI

Rigshospitalet

Chronic Recurrent Multifocal Osteomyelitis - a Bacterial Cause?

Chronic Recurrent Multifocal Osteomyelitis - Search for a Bacterial Cause and Improving Imaging With PET/MRI

Compare no. of detected CRMO lesions on PET/MRI and standard diagnostic tests

Marie Øbro Fosbøl

Medical doctor

Rigshospitalet, Denmark

Region Sjælland

Schnitzler Syndrome

CHU de Besançon Service de Dermatologie

Service de DermatologieCHU Morvan5 avenue Foch

Centre Hospitalier Général Bd Yves du Manoir

Service de Rhumatologie Centre Hospitalier du Mans

Service de Médecine Interne Hôpital Claude-Huriez

Service de DermatologieHôtel Dieu

Service médecine interne et thérapeutique Hôpital sainte marguerite

Service de Dermatologie Hôpital Saint Eloi 80 avenue A Fliche

Service de dermatologie CHU Hôtel Dieu1 place Alexis Ricordeau

Unité de médecine interne Centre Hospitalier G. Renon

Service de médecine interne Hôpital Tenon4, rue de la Chine

Service d'immuno-hématologie Hôpital St-Louis 1 av Claude Vellefaux

Service de dermatologieCHU GUERIN2 rue de la Milétrie

BOYE Thierry

Service de médecine interne-néphrologie Centre Hospitalier Valenciennes

Azienda Ospedaliero Universitaria Policlinico

Clinica DermatologicaUnivesité de GênesVialle Benedetto

Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors

Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic

University Hospital, Strasbourg, France

Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.

Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.

Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.

Double-blind adalimumab 40 mg every other week

DB Adalimumab 40 mg Eow

Double-blind adalimumab placebo every other week

Placebo Eow

Open-label adalimumab 40 mg every other week

OL Adalimumab 40 mg Eow

Total

Sex: Female, Male

Region of Enrollment

Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

Number of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment

Crohn's Disease Activity Index (CDAI) documents number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss during a 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 52 of Double-blind Treatment

Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

Clinical remission=Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Number of Participants Who Had Clinical Remission at Week 52 of Open-label Treatment

The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) score is an indicator of the activity of Crohn's disease. It measures absence (score of 0) or presence (score of 1) of abdominal pain, diarrhea or bloody stools more than 6 times per day, anal lesion, anal fistula, other complication, abdominal mass, weight loss, fever above 38 degrees Centigrade, abdominal tenderness, and blood pigment below 10 g/dL. Total possible score=0 to 10; low score=less disease activity. Decrease in score indicates alleviation of the disease; increase indicates aggravation of disease.

Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period. It has 32 questions about bowel function and related symptoms, and their social and emotional impact. For each item, participants select 1 of 7 responses. 1=poor quality of life (e.g., feeling of fatigue "all of the time") and 7=good quality (e.g., feeling of fatigue "none of the time"). Scoring range = 32 to 224. Higher scores indicate better quality of life; increases in IBDQ = improved overall quality of life.

Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 (Poorest Health) to 100 (Best Health).

Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 52 of Double-blind Treatment

Clinical remission = Crohn's Disease (CD) Activity Index (CDAI) <150; number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/aphthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI total score is >= 0 and without upper limit. Low score=less severe CD activity. Decrease indicates improvement.

All participants in this study who received at least 1 dose of adalimumab 40 mg every other week (double-blind or open-label).

Any Adalimumab

Number of Participants Who Had Clinical Remission at Week 148

Number of Participants Who Had Clinical Response-70 (CR-70; a Decrease in Crohn's Disease Activity Index of at Least 70 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

Number of Participants Who Had Clinical Response-100 (CR-100; a Decrease in Crohn's Disease Activity Index of at Least 100 Points From Lead-in Study [NCT00445939] Baseline Score) at Week 148

Crohn's Disease Activity Index (CDAI) is a measure of disease severity. Number of soft stools, abdominal pain, general well-being, presence of 6 signs (arthritis/arthralgia; iritis/uveitis; erythema nodosum/pyoderma gangrenosum/apthous stomatitis; fissure, abscess, anal fistula; other cutaneous fistula; fever over 100 degrees), taking medication for diarrhea, abdominal mass, hematocrit, and weight loss are documented during 1-week assessment period. CDAI has a total score >=0 and without upper limit. Low score=less severe CD activity. Decrease in score indicates improvement.

Change in Crohn's Disease Activity Index From Baseline of Lead-in Study (NCT00445939) to Week 148

Change in International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Score From Baseline of Lead-in Study (NCT00445939) to Week 148

IBDQ is a validated disease-specific instrument that assesses the impact of IBD on patient quality of life during a 2-week recall period with 32 questions about bowel function and related symptoms & their social/emotional impact. Per item, participants select 1 of 7 responses (1=poor quality of life [e.g., feeling of fatigue "all of the time"]; 7=good quality [e.g., feeling of fatigue "none of the time"]). Scoring range=32 to 224. Higher scores indicate better quality of life; increases in IBDQ=improved overall quality of life.

Change in Inflammatory Bowel Disease Questionnaire (IBDQ) From Baseline of Lead-in Study (NCT00445939) to Week 148

The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain, and rating of one's health. Score on the physical component ranges from 0 to 100, with 0=Poorest Health and 100=Best Health.

Change in Physical Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

The Short Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 indicates alleviation of the disease and a decrease in score indicates aggravation. The mental component reflects energy/vitality, social functioning, limitations, and ratings of one's mental health. Score on mental component ranges from 0 (worst score) to 100 (best score).

Change in Mental Component of the Short Form-36 Health Survey From Baseline of the Lead-in Study (NCT00445939) to Week 148

All participants in NCT00445432 (Study M06-837) who received at least 1 dose of adalimumab 40 mg every other week (double-blind or open-label).

Through Week 52 of NCT00445432 (M06-837)

148 Weeks of Adalimumab Treatment

Global Medical Services

Crohn's Disease

Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)

adalimumab

Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)

Placebo

Site Ref # / Investigator 46965

Site Ref # / Investigator 46977

Site Ref # / Investigator 46978

Site Ref # / Investigator 46979

Site Ref # / Investigator 46922

Site Ref # / Investigator 46974

Site Ref # / Investigator 46970

Site Ref # / Investigator 46971

Site Ref # / Investigator 46985

Site Ref # / Investigator 46986

Site Ref # / Investigator 46987

Site Ref # / Investigator 46968

Site Ref # / Investigator 46973

Site Ref # / Investigator 6881

Site Ref # / Investigator 46982

Site Ref # / Investigator 46969

Site Ref # / Investigator 46927

Site Ref # / Investigator 46984

Site Ref # / Investigator 46981

Site Ref # / Investigator 46921

Site Ref # / Investigator 46983

Site Ref # / Investigator 46966

Site Ref # / Investigator 46967

Site Ref # / Investigator 46980

Site Ref # / Investigator 46964

Site Ref # / Investigator 46923

Site Ref # / Investigator 46924

Site Ref # / Investigator 46975

Site Ref # / Investigator 46976

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

pyoderma gangrenosum/febre

Chronic Recurrent Multifocal Osteomyelitis - a Bacterial Cause?

Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

La base de dades d’herbes medicinals més completa avalada per la ciència